H.C. Wainwright Maintains Minerva Neurosciences(NERV.US) With Hold Rating, Maintains Target Price $5

Moomoo NewsNov 6, 2024 06:33 ET · Ratings

Minerva Neurosciences: Hold Rating Amid Regulatory Challenges and Uncertain Drug Development

TipRanksNov 6, 2024 06:16 ET · Ratings

Minerva Neurosciences Reports Positive Earnings Amid FDA Challenges

TipRanksNov 5, 2024 23:34 ET

Express News | Minerva Neurosciences Q3 2024 GAAP EPS $2.97 May Not Be Comparable To $(1.01) Estimate

BenzingaNov 5, 2024 08:04 ET

Minerva Neurosciences: Interactions With FDA Continue With Goal of Addressing Questions Raised in Roluperidone CRL >NERV

Dow JonesNov 5, 2024 07:32 ET

Minerva Neurosciences 3Q EPS $2.97 >NERV

Dow JonesNov 5, 2024 07:30 ET